Evidence map›Paper›PMID 35039847›Full record

ArticleJournal of radiation research2022

How should we appropriately classify low-risk uterine cervical cancer patients suitable for de-intensified treatment?

Naoya Murakami, Ikumi Kuno, Hiroshi Yoshida, Kouya Shiraishi, Tomoyasu Kato, Hiroshi Igaki

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of radiation research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Naoya MurakamiDepartment of Radiation Oncology, National Cancer Center Hospital, Tokyo, 104-0045, Japan.
Ikumi KunoDepartment of Gynecologic Oncology, National Cancer Center Hospital, Tokyo, 104-0045, Japan.
Hiroshi YoshidaDepartment of Diagnostic Pathology, National Cancer Center Hospital, Tokyo, 104-0045, Japan.
Kouya ShiraishiDivision of Genome Biology, National Cancer Center Research Institute, Tokyo, 104-0045, Japan.
Tomoyasu KatoDepartment of Gynecologic Oncology, National Cancer Center Hospital, Tokyo, 104-0045, Japan.
Hiroshi IgakiDepartment of Radiation Oncology, National Cancer Center Hospital, Tokyo, 104-0045, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We suggested de-escalation would be possible for cervical cancer like human papillomavirus (HPV)-related oropharyngeal cancer. However, the classification was based on tumor shrinkage that can be obtained after half of the treatment was finished. Our other article found adverse factors which can be obtained prior to treatment, and they might classify patients earlier.

Indexed as

Oropharyngeal NeoplasmsPapillomavirus InfectionsUterine Cervical NeoplasmsFemaleHumansPapillomaviridaeRiskde-escalationde-intensificationhuman papillomavirus (HPV)low-riskuterine cervical cancer

Identifiers

PMID35039847
PMCPMC8944302

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.